Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axi-Cel.24: Safety and Efficacy of Axicabtagene Ciloleucel in Relapsed/Refractory Large B Cell Lymphoma
jRCT1013240081Recruiting
- Sponsor
- Gilead Sciences
- Start
- Dec 2024
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of axicabtagene ciloleucel in diffuse large B-cell lymphoma (DLBCL), sponsored by Gilead Sciences. Primary endpoint: Response rate at 6 months after axi-cel administration. Started Dec 2024; status: recruiting.
02
Drugs
axicabtagene ciloleucel
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on jRCT1013240081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1013240081.